Quick answer
What is CJC-1295?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
CJC-1295 is a peptide, grouped on this site under GHRH analogues, and the 12 research records kept here are 2 from studies in rats or mice, 2 from trials in people and 8 that do not state what kind of study it is.
The literature search returned 36 records. This site keeps 12 of them, which is 33 per cent of what came back.
What it is
This site puts it in the GHRH analogues group.
A long-acting GHRH analogue that activates the GRF receptor; the retrieved literature attributes its extended duration of action to albumin bioconjugation.[1, 2]
Stated in the titles of the cited 2005 Endocrinology and 2009 Growth Hormone and IGF Research papers.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 2 interventional human trial records among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 24 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005). pmid:15817669
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res (2009). pmid:19386527